Avoid the trap: Targeting PARP1 beyond human malignancy

Chiho Kim, Chuo Chen, Yonghao Yu

Research output: Contribution to journalShort surveypeer-review

Abstract

PARP1 is a poly(ADP-ribose) polymerase (PARP) enzyme that plays a critical role in regulating DNA damage response. The main enzymatic function of PARP1 is to catalyze a protein post-translational modification known as poly(ADP-ribosyl)ation (PARylation). Human cancers with homologous recombination deficiency are highly sensitive to PARP1 inhibitors. PARP1 is aberrantly activated in many non-oncological diseases, leading to the excessive NAD+ depletion and PAR formation, thus causing cell death and tissue damage. PARP1 deletion offers a profound protective effect in the relevant animal models. However, many of the current PARP1 inhibitors also induce PARP1 trapping, which drives subsequent DNA damage, innate immune response and cytotoxicity. This minireview provides an overview of the basic biology of PARP1 trapping, and its implications in disease. Furthermore, we also discuss the recent development of PARP1 PROTAC compounds, and their utility as “non-trapping” PARP1 degraders for the potential amelioration of non-oncological diseases driven by aberrant PARP1 activation.

Original languageEnglish (US)
Pages (from-to)456-462
Number of pages7
JournalCell Chemical Biology
Volume28
Issue number4
DOIs
StatePublished - Apr 15 2021

Keywords

  • BRCA
  • NAD
  • PARP
  • breast cancer
  • cell death
  • ischemia reperfusion injury
  • neurodegeneration
  • ovarian cancer
  • phase transition
  • poly(ADP-ribose)
  • stroke

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Avoid the trap: Targeting PARP1 beyond human malignancy'. Together they form a unique fingerprint.

Cite this